The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.
Investigators shared data at an oncology meeting last week, showing that the test has high sensitivity and specificity in a blinded case-control cohort that included early-stage tumors.
The company reported no revenues in Q3 but said it has completed the transition to a new diagnostic platform for its DetermaVu liquid biopsy lung cancer test.
Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.
